EPHX2 and cardiac hypertrophy: Because of its central pathophysiologic role in disease states such as hypercholesterolemia, cardiac hypertrophy, diabetes, hypertension, ischemic stroke, cancer, arteriosclerosis, and pain, sEH is currently being investigated as a potential therapeutic target [19].